UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S456-S456

2017

Volltextzugriff (PDF)

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S143-S143

2016

Volltextzugriff (PDF)

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

Oncogene, 1998-10, Vol.17 (15), p.1949-1957

1998

Volltextzugriff (PDF)

TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence

International journal of cancer, 2001-10, Vol.94 (2), p.178-184

2001

Volltextzugriff (PDF)

BRCA1 expression levels predict distant metastasis of sporadic breast cancers

International journal of cancer, 1999-06, Vol.84 (3), p.258-262

1999

Volltextzugriff (PDF)

Identification of a novel member of the pentraxin family in Xenopus laevis

Proceedings of the Royal Society. B, Biological sciences, 1993-09, Vol.253 (1338), p.263

1993

Volltextzugriff (PDF)

Characterization of Ionomer Solutions. 1. Phase Behavior and Gelation of Sulfonated Polystyrene Ionomers in Decalin

Macromolecules, 1998-10, Vol.31 (21), p.7385-7389

1998

Volltextzugriff (PDF)

358PComplete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

358P - Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Annals of oncology, 2019-10, Vol.30, p.v130-v130

2019

Volltextzugriff (PDF)

Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Annals of oncology, 2019-10, Vol.30, p.v130

2019

Volltextzugriff (PDF)

Binding and orientation of fibronectin to silanated glass surfaces using immobilized bacterial adhesin-related peptides

Biomaterials, 2003-10, Vol.24 (22), p.3877-3884

2003

Volltextzugriff (PDF)

Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (PDA)

Annals of oncology, 2017-09, Vol.28, p.v265-v265

2017

Volltextzugriff (PDF)

LBA-02 High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study

Annals of oncology, 2015-06, Vol.26, p.iv117

2015

Volltextzugriff (PDF)

Characterization of Ionomer Solutions. 2. Dynamic Light Scattering Studies on Sulfonated Polystyrene Ionomers in a Nonpolar Solvent

Macromolecules, 1998-10, Vol.31 (21), p.7390-7397

1998

Volltextzugriff (PDF)

The Pedagogics of Unlearning

2016

Volltextzugriff (PDF)

FRI-098 - Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S456-S456

2017

Volltextzugriff (PDF)

437 - A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S143-S143

2016

Volltextzugriff (PDF)

Phase 3, randomized, double-blind, placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)+nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV pancreatic ductal adenocarcinoma (PDA)

Annals of oncology, 2017-11, Vol.28, p.x75-x76

2017

Volltextzugriff (PDF)

Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Annals of oncology, 2017-09, Vol.28, p.v261-v261

2017

Volltextzugriff (PDF)

Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Annals of oncology, 2017-09, Vol.28, p.v253-v254

2017

Volltextzugriff (PDF)

Political Theory for Mortals: Shades of Justice, Images of Death

Seery, John E

1, 2018

Volltextzugriff (PDF)

Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma

Annals of oncology, 2016-10, Vol.27, p.vi242-vi242

2016

Volltextzugriff (PDF)

Therapeutic approaches to the modulation of apoptosis

Essays in biochemistry, 2003-01, Vol.39, p.131-153

2003

Volltextzugriff (PDF)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report

Cancer management and research, 2015-01, Vol.7 (default), p.357-360

2015

Volltextzugriff (PDF)

THERMOPROCESSIBLE HYDROGELS. I. SYNTHESIS AND PROPERTIES OF POLYACRYLAMIDES WITH PERFLUOROALKYL SIDE CHAINS

Journal of macromolecular science. Part A, Pure and applied chemistry, 1999-01, Vol.36 (7-8), p.931-948

1999

Volltextzugriff (PDF)

1 – 25 von 1.316

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(977)
Mit Volltextzugriff
(1.069)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(427)
Electronic Journals Library
(423)
Lippincott Journal Package
(300)
MEDLINE
(296)
Publisher or Other Site
(238)
IngentaConnect Journals
(197)
Elsevier ScienceDirect Journals Complete
(188)
Ebook Central Perpetual and DDA
(119)
eBooks on EBSCOhost
(111)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(102)
Wiley Online Library
(96)
De Gruyter eBooks
(88)
Springer Online Journals
(81)
JSTOR
(76)
Nexis Uni
(64)
Taylor & Francis Online
(63)
Taylor & Francis
(62)
ERIC
(60)
SAGE Journals
(55)
Business Source Ultimate
(54)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence

BRCA1 expression levels predict distant metastasis of sporadic breast cancers

Identification of a novel member of the pentraxin family in Xenopus laevis

Characterization of Ionomer Solutions. 1. Phase Behavior and Gelation of Sulfonated Polystyrene Ionomers in Decalin

358PComplete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

358P - Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Binding and orientation of fibronectin to silanated glass surfaces using immobilized bacterial adhesin-related peptides

Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (PDA)

LBA-02 High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study

Characterization of Ionomer Solutions. 2. Dynamic Light Scattering Studies on Sulfonated Polystyrene Ionomers in a Nonpolar Solvent

The Pedagogics of Unlearning

FRI-098 - Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma

437 - A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

Phase 3, randomized, double-blind, placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)+nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV pancreatic ductal adenocarcinoma (PDA)

Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Political Theory for Mortals: Shades of Justice, Images of Death

Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma

Therapeutic approaches to the modulation of apoptosis

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report

THERMOPROCESSIBLE HYDROGELS. I. SYNTHESIS AND PROPERTIES OF POLYACRYLAMIDES WITH PERFLUOROALKYL SIDE CHAINS

Suchergebnisse filtern